The company remains a pre-revenue entity with no top-line generation, while R&D intensity continues to drive operating losses that peaked at $4.4 million in 2024Q2.
| Sales/Revenue | 0 | 0 | 0 | 55.18K | 140.11K | 164.99K | 28.88K | 41.3K | 20.61K |
| Revenue Growth % | - | - | -100% | -60.62% | -15.08% | 471.29% | -30.07% | 100.4% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 55.18K | 140.11K | 164.99K | 28.88K | 41.3K | 20.61K |
| Gross Margin % | - | - | - | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | - | -100% | -60.62% | -15.08% | 471.29% | -30.07% | 100.4% | - |
| Operating Expenses | 19.69M | 18.71M | 20.35M | 22.31M | 17.92M | 13.99M | 3.51M | 2.14M | 1.05M |
| OpEx % of Revenue | - | - | - | 40428.26% | 12788.1% | 8479.8% | 12147.54% | 5184.89% | 5089.65% |
| Selling, General & Admin | 8.98M | 8.5M | 9.56M | 10.79M | 9.54M | 6.83M | 1.25M | 555.16K | 222.05K |
| SG&A % of Revenue | - | - | - | 19550.02% | 6808.94% | 4137.69% | 4325.08% | 1344.19% | 1077.43% |
| Research & Development | 10.72M | 10.21M | 10.79M | 11.52M | 8.38M | 7.16M | 2.26M | 1.59M | 826.88K |
| R&D % of Revenue | - | - | - | 20878.24% | 5979.17% | 4342.11% | 7822.46% | 3840.69% | 4012.23% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -19.69M | -18.71M | -20.35M | -22.25M | -17.78M | -13.83M | -3.48M | -2.1M | -1.03M |
| Operating Margin % | - | - | - | -40328.26% | -12688.1% | -8379.8% | -12047.54% | -5084.89% | -4989.65% |
| Operating Income Growth % | - | 8.06% | 8.55% | -25.18% | -28.58% | -297.37% | -65.68% | -104.23% | - |
| EBITDA | -19.6M | -18.62M | -20.27M | -22.17M | -17.71M | -13.81M | -3.47M | -2.1M | -1.03M |
| EBITDA Margin % | - | - | - | -40176.79% | -12642.3% | -8370.42% | -12014.32% | -5078.66% | -4986.06% |
| EBITDA Growth % | 3.25% | 8.14% | 8.58% | -25.16% | -28.25% | -298.02% | -65.43% | -104.12% | - |
| D&A (Non-Cash Add-back) | 94.69K | 94.05K | 84.07K | 83.58K | 64.17K | 15.48K | 9.59K | 2.57K | 741 |
| EBIT | -19.69M | -18.71M | -20.35M | -22.25M | -17.78M | -13.83M | -3.48M | -2.1M | -1.03M |
| Net Interest Income | 218.96K | 244.39K | 357.1K | 494.23K | 375.36K | 12.49K | 3.64K | -20.54K | -52.48K |
| Interest Income | 218.96K | 244.39K | 357.1K | 494.23K | 375.36K | 12.49K | 3.64K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.54K | 52.48K |
| Other Income/Expense | -601.23K | -589.28K | 476.22K | 64.89K | 279.28K | -60.42K | -92.85K | -86.22K | -67.44K |
| Pretax Income | -20.3M | -19.3M | -19.87M | -22.19M | -17.5M | -13.89M | -3.57M | -2.19M | -1.1M |
| Pretax Margin % | - | - | - | -40210.67% | -12488.77% | -8416.43% | -12369.02% | -5293.65% | -5316.9% |
| Income Tax | 943.67K | 861.12K | 536.82K | 79.28K | 92.98K | 4.01K | 5.39K | 7.11K | 9.78K |
| Effective Tax Rate % | -4.65% | -4.46% | -2.7% | -0.36% | -0.53% | -0.03% | -0.15% | -0.33% | -0.89% |
| Net Income | -21.24M | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M | -3.58M | -2.19M | -1.11M |
| Net Margin % | - | - | - | -40354.33% | -12555.13% | -8418.86% | -12387.67% | -5310.88% | -5364.36% |
| Net Income Growth % | -1.49% | 1.23% | 8.34% | -26.59% | -26.64% | -288.26% | -63.11% | -98.4% | - |
| Net Income (Continuing) | -21.24M | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M | -3.58M | -2.19M | -1.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.50 | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -0.30 | -0.26 | -0.19 |
| EPS Growth % | 34.83% | 31.46% | 47.95% | -15.54% | -8.03% | -356.67% | -15.38% | -36.84% | - |
| EPS (Basic) | - | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -0.30 | -0.37 | -0.19 |
| Diluted Shares Outstanding | 42.23M | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 11.88M | 8.37M | 5.86M |
| Basic Shares Outstanding | 42.23M | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 11.88M | 8.37M | 5.86M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Clinical trial funding shortfall
As indicated by the company's financial disclosures, Gain Therapeutics remains a pre-revenue entity, with no top-line generation recorded across the last ten quarters, underscoring its status as a purely development-stage biotechnology firm reliant on external capital rather than product sales to fund its ongoing research initiatives.
The lack of revenue confirms that the company's value proposition is entirely tied to future clinical milestones rather than current market penetration. Investors should monitor the transition from grant-funded research to potential licensing revenue, as the current model provides no organic growth signal to evaluate.
Based on reported quarterly filings, the company consistently directs the majority of its capital toward R&D, which reached a peak of $4.4 million in 2024Q2, reflecting the high fixed costs inherent in validating the SEE-Tx platform through human clinical trials for lead candidates like GT-02287.
The cost structure is heavily skewed toward research, which appears to be the primary driver of the persistent operating losses. Management's expense discipline is difficult to assess given the necessity of these clinical expenditures, but the volatility in quarterly R&D spend suggests that trial enrollment phases create significant, non-linear cash outflows.
According to the provided income statement data, stock-based compensation has remained a consistent feature of the expense profile, peaking at $1.5 million in 2024Q2, which suggests that the reported net losses may understate the true cash-based operational burn required to retain specialized computational biology talent.
The reliance on equity-based incentives is typical for early-stage biotech, yet it complicates the assessment of true operational efficiency. Analysts should adjust for these non-cash charges to better understand the underlying cash runway, as the current net loss figures do not fully capture the dilution impact on existing shareholders.
With a cash position of approximately $20.8 million and quarterly operating losses frequently exceeding $4 million, as noted in recent financial summaries, the company faces a narrowing window of liquidity that may necessitate dilutive financing events to sustain its clinical development pipeline over the next twelve months.
The current burn rate suggests that the company is approaching a critical juncture where its ability to fund operations will be tested by the capital markets. Investors should be wary of the potential for significant equity dilution, which may occur if the company fails to secure non-dilutive partnership milestones in the near term.
Quick answers to the most common questions about buying GANX stock.
For fiscal year 2025, Gain Therapeutics, Inc. (GANX) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.0M in 2018.
Gain Therapeutics, Inc. (GANX) reported a net loss of $20.2M for the fiscal year ending 2025.